Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.6 0.00% 0.00
ACRX closed unchanged on Thursday, April 27, 2017, on 44 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 1

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Apr 25 Reversal New Lows Setup Bearish Swing Setup 1.96%
Apr 24 Doji - Bullish? Reversal 0.00%
Apr 21 Stochastic Reached Oversold Other 1.96%
Apr 21 New Downtrend Bearish 1.96%
Apr 20 Calm After Storm Range Contraction -3.70%
Apr 19 Narrow Range Bar Range Contraction -1.89%
Apr 19 Lower Bollinger Band Walk Other -1.89%
Apr 19 180 Bearish Setup Bearish Swing Setup -1.89%
Apr 19 Calm After Storm Range Contraction -1.89%
Apr 18 Lower Bollinger Band Walk Other -3.70%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company’s principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. In addition, the company’s product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.08
52 Week Low 2.4
Average Volume 200,843
200-Day Moving Average 3.0889
50-Day Moving Average 2.974
20-Day Moving Average 2.7738
10-Day Moving Average 2.645
Average True Range 0.1313
ADX 29.93
+DI 12.57
-DI: 25.14
Chandelier Exit (Long, 3 ATRs) 2.8061
Chandelier Exit (Short, 3 ATRs) 2.8939
Upper Bollinger Band 3.1369
Lower Bollinger Band 2.4107
Percent B (%b) 0.26
Bandwidth 0.261807